Follicular Lymphoma Treatment Market Report 2026

The follicular lymphoma treatment market size has grown strongly in recent years. It will grow from $3.28 billion in 2025 to $3.54 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to advancements in monoclonal antibodies, increased awareness of lymphoma, growth of oncology research, expansion of hospital infrastructure, rising incidence of non-hodgkin lymphoma.

The follicular lymphoma treatment market size is expected to see strong growth in the next few years. It will grow to $4.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to innovation in targeted therapy, integration of ai in treatment planning, growth in stem cell transplant procedures, expansion of oncology centers in emerging markets, development of biosimilars. Major trends in the forecast period include personalized treatment protocols, development of novel monoclonal antibodies, combination therapy approaches, early diagnosis and screening initiatives, minimally invasive treatment techniques.

The increasing prevalence of follicular lymphoma is anticipated to drive the expansion of the follicular lymphoma treatment market in the coming years. The prevalence of follicular lymphoma refers to the number or proportion of individuals within a defined population who are diagnosed with the disease over a specific period. This increase is attributed to factors such as an aging population, genetic susceptibility, advances in diagnostic technologies, and greater awareness and screening efforts. Treatments for follicular lymphoma play a key role in managing the disease at different stages, slowing progression, and improving patient outcomes. As the incidence of follicular lymphoma continues to rise, demand for effective treatment options is supporting market growth. For example, in January 2023, according to the American Cancer Society, non-Hodgkin lymphoma, which includes indolent forms such as follicular lymphoma, accounted for about 4% of all cancers in the United States. The organization projected that approximately 80,550 people, including 44,880 men and 35,670 women, would be diagnosed with non-Hodgkin lymphoma, encompassing both adults and children. Therefore, the rising prevalence of follicular lymphoma is contributing to the growth of the follicular lymphoma treatment market.

Major companies operating in the follicular lymphoma treatment market are concentrating on the development of advanced therapies such as bispecific antibodies to achieve durable remission while reducing treatment burden for patients. Bispecific antibodies are engineered molecules designed to bind two distinct targets simultaneously, for example, attaching to a tumor antigen on B cells while also engaging T cells, thereby redirecting the immune system to more effectively eliminate cancer cells. For instance, in March 2025, Chugai Pharmaceutical, a Japan-based research-driven oncology company, launched LUNSUMIO, which utilizes a CD20/CD3 bispecific antibody mechanism. LUNSUMIO is approved as an intravenous infusion in 1 mg and 30 mg doses for patients with relapsed or refractory follicular lymphoma who have not responded to at least two prior standard therapies. The treatment is administered for a fixed duration based on individual patient response, helping to lower long-term treatment burden. Clinical data have shown high complete response rates, with the potential to deliver durable remission as a monotherapy.

In December 2024, Innate Pharma, a France-based developer of immunotherapy-based cancer treatments, partnered with the Institute for Follicular Lymphoma Innovation to support the clinical development of its IPH6501 program. Through this collaboration, Innate Pharma aims to accelerate the advancement of its ANKET-based bispecific immunotherapy for patients with relapsed or refractory follicular lymphoma by leveraging IFLI’s targeted funding and specialized expertise in lymphoma research.

Major companies operating in the follicular lymphoma treatment market are AbbVie Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson and Johnson Services Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Boehringer Ingelheim GmbH, CTI BioPharma Corp., Spectrum Pharmaceuticals Inc., Seattle Genetics Inc., Daiichi Sankyo Company Ltd., Pfizer Inc., Incyte Corporation, MorphoSys AG, Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Seagen Inc., Takeda Pharmaceutical Company, Nordic Nanovector ASA, ADC Therapeutics SA, MEI Pharma Inc., BeiGene Inc., TG Therapeutics Inc., Amgen Inc.

North America was the largest region in the follicular lymphoma treatment market in 2025. The regions covered in the follicular lymphoma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the follicular lymphoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the follicular lymphoma treatment market by increasing the cost of imported biologics, chemotherapy drugs, and medical equipment, creating challenges in treatment affordability and supply chain efficiency. The segments most affected include monoclonal antibodies and targeted therapy, particularly in regions like North America and Europe that rely on imported specialty drugs. While tariffs may slow market growth, they also encourage local manufacturing and domestic production of treatments, which could enhance supply resilience and reduce long-term dependency on imports.

The follicular lymphoma treatment market research report is one of a series of new reports that provides follicular lymphoma treatment market statistics, including follicular lymphoma treatment industry global market size, regional shares, competitors with a follicular lymphoma treatment market share, detailed follicular lymphoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the follicular lymphoma treatment industry. This follicular lymphoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Follicular lymphoma treatment involves medical interventions and therapies designed to manage and slow the progression of follicular lymphoma, a type of non-Hodgkin lymphoma marked by abnormal cell growth within the lymphatic system. Medications are commonly administered intravenously, and radiation therapy may be used to treat early-stage follicular lymphoma.

The main treatment types for follicular lymphoma include monoclonal antibodies, targeted therapy, chemotherapy, radiation therapy, stem cell transplantation, alkylating agents, nucleoside analogues, anthracycline derivatives, and others. Monoclonal antibodies are laboratory-engineered proteins created to replicate the immune system’s ability to recognize and bind to specific targets in the body. In follicular lymphoma treatment, they are used to target specific proteins on the surface of cancer cells and activate the immune response. The various product forms used in follicular lymphoma treatment include tablets, capsules, injectables, and others, which are administered through oral, parenteral, and other routes. These treatments are provided in hospitals, oncology centers, ambulatory care centers, academic and research institutes, and other healthcare settings.

The follicular lymphoma treatment market includes revenues earned by entities by providing drugs, medications, diagnostic devices, radiation therapy equipment, surgical instruments, and devices. Therapies that are used in the treatment of follicular lymphoma. The follicular lymphoma treatment market includes surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy, and supportive care.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.